Literature DB >> 23743439

Aqueous flare and choroidal thickness in patients with chronic hepatitis C virus infection: a pilot study.

Ernesto Strobbe1, Mauro Cellini, Emilio C Campos.   

Abstract

PURPOSE: To investigate the status of the blood-aqueous barrier and to evaluate the subfoveal choroidal thickness (SCT) in patients with asymptomatic untreated chronic hepatitis C virus (HCV) infection without any anterior or posterior ocular involvement and to search for possible correlations.
DESIGN: Observational case-control study. PARTICIPANTS AND CONTROLS: A total of 80 eyes of 20 HCV-positive patients (male-to-female ratio, 12:8; mean age, 46.9±7.23 years) and 20 healthy controls (male-to-female ratio, 10:10; mean age, 48.2±8.71 years) were examined.
METHODS: Participants underwent a complete ophthalmologic examination. Aqueous flare was quantified objectively by using the noninvasive laser flare cell meter FC-500 (Kowa Company Ltd, Tokyo, Japan), whereas SCT was evaluated by using enhanced depth imaging optical coherence tomography (Spectralis OCT; Heidelberg Engineering GmbH, Heidelberg, Germany). A Wilcoxon rank-sum test was performed to compare ocular findings between HCV patients and controls, and correlations were assessed by using the Spearman rank test. MAIN OUTCOME MEASURES: Retinal and choroidal thickness and anterior chamber inflammation of HCV patients and healthy controls.
RESULTS: Patients with HCV showed significantly higher aqueous flare values (8.37±2.25 photon counts/ms vs. 4.56±1.45 photon counts/ms; P<0.0001) and a significantly increased SCT (362.7±46.5 μm vs. 320.25±32.82 μm; P<0.0001) than healthy controls. Moreover, subjects with liver fibrosis had higher flare values than those with no significant hepatic fibrosis (9.62±1.99 photon counts/ms vs. 6.97±2.19 photon counts/ms; P = 0.0003) and thicker choroids (379.15±44.75 μm vs. 346.3±43.27 μm; P = 0.024). Statistical analysis revealed that there was a positive correlation between aqueous flare values and SCT in HCV patients (r = 0.69; P<0.0001) and between flare and the degree of liver fibrosis (r = 0.67; P = 0.0001).
CONCLUSIONS: This study showed that impairment of the blood-aqueous barrier and thickened choroids are features of asymptomatic HCV patients, and that choroidal thickness increases as the degree of subclinical inflammation of the anterior chamber increases. Patients with significant liver fibrosis have the highest flare values and the thickest choroids.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23743439     DOI: 10.1016/j.ophtha.2013.03.040

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

Review 1.  Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology.

Authors:  Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2016-11-25       Impact factor: 2.447

2.  Choroidal Thickening in Patients with Sleep Apnea Syndrome.

Authors:  Metin Ekinci; Nergiz Hüseyinoğlu; H Hüseyin Çağatay; Sadullah Keleş; Erdinç Ceylan; Gökçen Gökçe
Journal:  Neuroophthalmology       Date:  2014-01-28

3.  RELATIONSHIP BETWEEN UVEITIS, DIFFERENT TYPES OF VIRAL HEPATITIS, AND LIVER CIRRHOSIS: A 12-Year Nationwide Population-Based Cohort Study.

Authors:  Peng-Tai Tien; Chun-Ju Lin; Yi-Yu Tsai; Huan-Sheng Chen; De-Kuang Hwang; Chih-Hsin Muo; Jane-Ming Lin; Wen-Lu Chen
Journal:  Retina       Date:  2016-12       Impact factor: 4.256

4.  Choroidal Thickness in Diabetes and Diabetic Retinopathy: A Swept Source OCT Study.

Authors:  Wei Wang; Sen Liu; Zhihan Qiu; Miao He; Lanhua Wang; Yuting Li; Wenyong Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-04-09       Impact factor: 4.799

Review 5.  Changes of Subfoveal Choroidal Thickness after Cataract Surgery: A Meta-Analysis.

Authors:  Shaoxue Zeng; Chen Liang; Yueqing He; Yingying Chen; Qing Zhao; Shuiping Dai; Fengrui Cheng; Junjun Zhang; Xiaoshuang Jiang
Journal:  J Ophthalmol       Date:  2018-11-12       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.